# Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease

> **NCT01862536** · PHASE2 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 44 (actual)

## Conditions studied

- Pulmonary Hypertension
- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Tadalafil
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01862536
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-01
- **Primary completion:** 2019-08-31
- **Final completion:** 2019-08-31
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2021-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01862536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01862536, "Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01862536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*